Research
Management of hereditary angioedema: 2010 Canadian approach
-
* Corresponding author: Tom Bowen tbowen@pol.net
1 Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH), 705 South Tower, 3031 Hospital Dr. NW Calgary, Alberta, Canada
2 Departments of Medicine and Paediatrics, University of Calgary, Calgary, Alberta, Canada
3 Patient Advisory Committee, CHAEN/RCAH. 705 South Tower, 3031 Hospital Dr. NW, Calgary, Alberta, Canada
4 Department of Medicine, Laval University, Quebec City, Quebec, Canada
5 Departments of Medicine and Medical Oncology, University of Alberta, Edmonton, Alberta, Canada
Allergy, Asthma & Clinical Immunology 2010, 6:20 doi:10.1186/1710-1492-6-20
Published: 28 July 2010Abstract
C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH) - http://www.haecanada.com webcite to advance care of patients with this disorder in Canada. We here present a review of management of HAE in Canada.